



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/831,149		Roelof W Feenstra	01975.0031	1033

7590 10/07/2003

Finnegan Henderson Farabow
Garrett & Dunner
1300 I Street N W
Washington, DC 20005-3315

EXAMINER

LIU, HONG

ART UNIT	PAPER NUMBER
----------	--------------

1624

DATE MAILED: 10/07/2003

9

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/831,149

Applicant(s)

FEENSTRA, ROELOF W

Examiner

Hong Liu

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) 1-11 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☒ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Claims 1-11 are pending in this application.

Specification

This application does not contain an abstract of the disclosure as required by 37

CFR 1.72(b). An abstract on a separate sheet is required.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. Claims 1-11 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for preparation and use of compounds wherein R1 and R2 do not form a bridge, does not reasonably provide enablement for preparation and use of compounds wherein R and R2 form a bridge. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The nature of the invention in the instant application has claims which embrace a diversity of chemically and physically distinct compounds, wherein R1 and R2 form a bridge such that the substituent attached to the benzoxazole is a bicyclic ring. While a few compounds are disclosed, there is insufficient guidance for preparing additional dopamine receptor agonist which could be effective since the cited examples are drawn to a homogenous group of

Art Unit: 1624

compounds not remotely commensurate in scope to applicants' claims. Only compounds wherein R1 and R2 do not form a bridge have been made.

Furthermore, no testing data is provided for the compounds. The definitions of the various R variables embrace many structurally divergent groups not represented at all in testing, since testing for the instant compounds is not seen in the specification. Markush claims must be provided with support in the disclosure when the "working examples" fail to include written description(s) which teach how to make and use Markush members embraced thereby in full, clear and exact terms. See *In re Fouch*, 169 USPQ 429.

This area of activity can be expected to be highly structure specific and unpredictable, as is generally true for chemically-based pharmacological activity. In view of the structural divergence in the claims, one skilled in the art could not reasonably extrapolate the activities of some of the claimed compounds to the other structurally divergent compounds embraced by the claims which have not been tested. In cases directed to chemical compounds which are being used for their physiological activity, the scope of the claims must have a reasonable correlation to the scope of enablement provided by the specification. See *In re Surrey* 151 USPQ 724 regarding sufficiency of disclosure for a Markush group. No reasonable assurance has been made that the instant compounds as an entire class have the required activities needed to practice the invention.

Thus, factors such as "sufficient working examples", "the level of skill in the art" and "predictability" have been demonstrated to be sufficiently lacking in the instant case for the scope being claimed.

Art Unit: 1624

Claim 10 is drawn to a method of treating CNS disorders. This claim is interpreted to include any and all disorders associated with this particular mode of action. The specification reads on any and all CNS disorders. However, the applicant discloses on P.3 of the specification that the compounds are “likely” to be of value in the treatment of affections or diseases of the central nervous system, “caused by disturbances of the dopaminergic and/or serotonergic systems.” The specification only discusses the potential use of the compounds in the treatment of anxiety and depression. Furthermore, no evidence of in vitro/in vivo effectiveness is seen in the specification for one of the (let alone all) of the instant compounds for the uses claimed herein. See *In re Surrey*, 252 USPQ 724, regarding sufficiency of disclosure. Competent evidence of art-recognized efficacy for intended uses needs to be provided. Any evidence presented must be commensurate in scope with the claims and must clearly demonstrate the likelihood of in vivo use for all uses being claimed. See *Ex parte Powers*, 220 USPQ 925.

Claim 1 is also rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The scope of “prodrug” is not adequately enabled. Applicants provide no guidance as how the compounds are made more active in vivo. The choice of a “prodrug” will vary from drug to drug. Therefore, more than minimal routine experimentation would be required to determine which prodrug will be suitable for the instant invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 10 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 10 is of indeterminate scope for more than one reason. First, no one particular disorder is recited. Second, the claim language may read on diseases not yet fully understood to be affected by dopamine receptor agonists.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kruse et al. (EP 0190472). The reference teaches a generic group of compounds which embraces applicant's instantly claimed compounds. See formula on page I wherein A forms an entirely or partly unsaturated ring consisting of 5-atoms, which ring comprises at least one oxygen atom, B is alkyl, etc. The compounds are taught to be useful as pharmaceutical agents for anti-psychosis. The compounds made in the reference had a benzofuran core which differs from the benzoxazole core of the instant claims. However, the reference teaches the equivalence of the two types of cores by the definition of A. Thus it would have been obvious to one skilled in the art at the time of the invention to be motivated to select any of the species of the genus taught by the reference including those instantly claimed, because the skilled chemist would have the reasonable expectation that any of the species of the genus would have similar properties and, thus, the same

Art Unit: 1624


use as taught for the genus as a whole. It has been held that a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. See *In re Susi*, 440 F.2d 442, 169 USPQ 423, 425 (CCPA 1971), followed by the Federal Circuit in *Merck & Co. V. Biocraft Laboratories*, 847 F.2d 804, 10 USPQ 2d 1843, 1846 (Fed. Cir. 1989).


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hong Liu whose telephone number is 703 3065814. The examiner can normally be reached on 8:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703 308 4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308-4556 for regular communications and 703 3084734 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 358-1235.

hl
October 6, 2003

 **Mukund Shah**
Supervisory Patent Examiner
Art Unit 1624


JOHN M. FORD
PRIMARY EXAMINER
GROUP - ART UNIT 1624